Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular Route in Participants Aged 65 Years and Older
Phase of Trial: Phase III
Latest Information Update: 23 May 2018
At a glance
- Drugs Influenza virus vaccine (Primary)
- Indications Influenza virus infections
- Focus Pharmacodynamics
- Sponsors sanofi pasteur
- 23 Apr 2018 Status changed from active, no longer recruiting to completed.
- 07 Nov 2017 Planned End Date changed from 27 Oct 2017 to 28 Mar 2018.
- 20 Sep 2017 New trial record